North American Vaccine Inc. said it has executed a licenseagreement with Harvard University for patented technology tobe used in the development of a vaccine against Group Bstreptococcus infections. Terms were not disclosed.

The Food and Drug Administration has not approved any vaccinefor Group B streptococcus, according to the company. Thedisease is a bacterial infection that principally occurs duringthe first two months of life and can cause death or permanentbrain damage resulting from meningitis.

The license is for a Group B polysaccharide that the companywill chemically couple to a carrier protein to make a conjugatevaccine. The Beltsville, Md., company (AMEX:NVX) said it willcollaborate with Harvard in the clinical development of thevaccine. -- Steve Usdin

(c) 1997 American Health Consultants. All rights reserved.